Indication
Endometrial carcinoma
Endometrial carcinoma is a primary epithelial malignancy originating in the endometrium, the inner mucosal lining of the uterine corpus. Read more about Endometrial carcinoma
17 drugs 14 manufacturers
Drugs that treat it
Common Endometrial carcinoma therapies.
MEGESTROL (megestrol acetate)
MEGESTROL ACETATE
MEGESTROL ACETATE
MEGESTROL ACETATE
MEGESTROL ACETATE
KEYTRUDA POWDER (pembrolizumab)
KEYTRUDA (pembrolizumab)
LENVIMA (lenvatinib mesylate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonEndometrial carcinoma is a primary epithelial malignancy originating in the endometrium, the inner mucosal lining of the uterine corpus.
It is the most common gynecologic malignancy, predominantly affecting postmenopausal individuals and typically presenting clinically with abnormal uterine bleeding or pelvic pain.
Pathophysiologically, it encompasses diverse subtypes, most commonly low-grade endometrioid adenocarcinomas linked to prolonged unopposed estrogen exposure, as well as aggressive, non-hormone-driven non-endometrioid variants such as serous and clear cell carcinomas.
Contemporary classification further incorporates molecular profiles, including DNA polymerase epsilon mutations, mismatch repair deficiency, p53 abnormalities, and copy-number alterations, which dictate tumor behavior and clinical risk.
- cancer.gov
Endometrial carcinoma is a primary epithelial malignancy originating in the endometrium, the inner mucosal lining of the uterine corpus
- nih.gov
Endometrial carcinoma is a primary epithelial malignancy originating in the endometrium, the inner mucosal lining of the uterine corpus It is the most common gynecologic malignancy, predominantly affecting postmenopausal individuals and typically presenting clinically with abnormal uterine bleeding or pelvic pain Contemporary classification further incorporates molecular profiles, including DNA polymerase epsilon mutations, mismatch repair deficiency, p53 abnormalities, and copy-number alteratio...
- nih.gov
It is the most common gynecologic malignancy, predominantly affecting postmenopausal individuals and typically presenting clinically with abnormal uterine bleeding or pelvic pain Pathophysiologically, it encompasses diverse subtypes, most commonly low-grade endometrioid adenocarcinomas linked to prolonged unopposed estrogen exposure, as well as aggressive, non-hormone-driven non-endometrioid variants such as serous and clear cell carcinomas
- cancer.gov
Pathophysiologically, it encompasses diverse subtypes, most commonly low-grade endometrioid adenocarcinomas linked to prolonged unopposed estrogen exposure, as well as aggressive, non-hormone-driven non-endometrioid variants such as serous and clear cell carcinomas
- medlineplus.gov
Pathophysiologically, it encompasses diverse subtypes, most commonly low-grade endometrioid adenocarcinomas linked to prolonged unopposed estrogen exposure, as well as aggressive, non-hormone-driven non-endometrioid variants such as serous and clear cell carcinomas
- nih.gov
Pathophysiologically, it encompasses diverse subtypes, most commonly low-grade endometrioid adenocarcinomas linked to prolonged unopposed estrogen exposure, as well as aggressive, non-hormone-driven non-endometrioid variants such as serous and clear cell carcinomas Contemporary classification further incorporates molecular profiles, including DNA polymerase epsilon mutations, mismatch repair deficiency, p53 abnormalities, and copy-number alterations, which dictate tumor behavior and clinical ris...
Personalize your experience
Follow Endometrial carcinoma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.